377 related articles for article (PubMed ID: 32895485)
1. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.
Li Y; Lai DY; Zhang HN; Jiang HW; Tian X; Ma ML; Qi H; Meng QF; Guo SJ; Wu Y; Wang W; Yang X; Shi DW; Dai JB; Ying T; Zhou J; Tao SC
Cell Mol Immunol; 2020 Oct; 17(10):1095-1097. PubMed ID: 32895485
[No Abstract] [Full Text] [Related]
2. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
[TBL] [Abstract][Full Text] [Related]
3. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
4. On the molecular determinants of the SARS-CoV-2 attack.
Kanduc D; Shoenfeld Y
Clin Immunol; 2020 Jun; 215():108426. PubMed ID: 32311462
[No Abstract] [Full Text] [Related]
5. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
7. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Shi R; Shan C; Duan X; Chen Z; Liu P; Song J; Song T; Bi X; Han C; Wu L; Gao G; Hu X; Zhang Y; Tong Z; Huang W; Liu WJ; Wu G; Zhang B; Wang L; Qi J; Feng H; Wang FS; Wang Q; Gao GF; Yuan Z; Yan J
Nature; 2020 Aug; 584(7819):120-124. PubMed ID: 32454512
[TBL] [Abstract][Full Text] [Related]
8. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.
Lin L; Ting S; Yufei H; Wendong L; Yubo F; Jing Z
Virus Res; 2020 Oct; 288():198082. PubMed ID: 32621841
[TBL] [Abstract][Full Text] [Related]
9. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy.
Du S; Cao Y; Zhu Q; Yu P; Qi F; Wang G; Du X; Bao L; Deng W; Zhu H; Liu J; Nie J; Zheng Y; Liang H; Liu R; Gong S; Xu H; Yisimayi A; Lv Q; Wang B; He R; Han Y; Zhao W; Bai Y; Qu Y; Gao X; Ji C; Wang Q; Gao N; Huang W; Wang Y; Xie XS; Su XD; Xiao J; Qin C
Cell; 2020 Nov; 183(4):1013-1023.e13. PubMed ID: 32970990
[TBL] [Abstract][Full Text] [Related]
10. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.
Piccoli L; Park YJ; Tortorici MA; Czudnochowski N; Walls AC; Beltramello M; Silacci-Fregni C; Pinto D; Rosen LE; Bowen JE; Acton OJ; Jaconi S; Guarino B; Minola A; Zatta F; Sprugasci N; Bassi J; Peter A; De Marco A; Nix JC; Mele F; Jovic S; Rodriguez BF; Gupta SV; Jin F; Piumatti G; Lo Presti G; Pellanda AF; Biggiogero M; Tarkowski M; Pizzuto MS; Cameroni E; Havenar-Daughton C; Smithey M; Hong D; Lepori V; Albanese E; Ceschi A; Bernasconi E; Elzi L; Ferrari P; Garzoni C; Riva A; Snell G; Sallusto F; Fink K; Virgin HW; Lanzavecchia A; Corti D; Veesler D
Cell; 2020 Nov; 183(4):1024-1042.e21. PubMed ID: 32991844
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
[TBL] [Abstract][Full Text] [Related]
12. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
13. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Vojdani A; Kharrazian D
Clin Immunol; 2020 Aug; 217():108480. PubMed ID: 32461193
[No Abstract] [Full Text] [Related]
14. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
15. Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.
Wan J; Xing S; Ding L; Wang Y; Gu C; Wu Y; Rong B; Li C; Wang S; Chen K; He C; Zhu D; Yuan S; Qiu C; Zhao C; Nie L; Gao Z; Jiao J; Zhang X; Wang X; Ying T; Wang H; Xie Y; Lu Y; Xu J; Lan F
Cell Rep; 2020 Jul; 32(3):107918. PubMed ID: 32668215
[TBL] [Abstract][Full Text] [Related]
16. Recovered COVID-19 patients with recurrent viral RNA exhibit lower levels of anti-RBD antibodies.
Liu B; Shi Y; Zhang W; Li R; He Z; Yang X; Pan Y; Deng X; Tan M; Zhao L; Zou F; Zhang Y; Pan T; Zhang J; Zhang X; Xiao F; Li F; Deng K; Zhang H
Cell Mol Immunol; 2020 Oct; 17(10):1098-1100. PubMed ID: 32939033
[No Abstract] [Full Text] [Related]
17. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
[TBL] [Abstract][Full Text] [Related]
18. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19.
Xu W; Wang M; Yu D; Zhang X
Front Immunol; 2020; 11():565278. PubMed ID: 33013929
[TBL] [Abstract][Full Text] [Related]
19. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
[TBL] [Abstract][Full Text] [Related]
20. Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2.
Yu F; Xiang R; Deng X; Wang L; Yu Z; Tian S; Liang R; Li Y; Ying T; Jiang S
Signal Transduct Target Ther; 2020 Sep; 5(1):212. PubMed ID: 32963228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
